Using data and technology to improve healthcare ecosystems.

we explain how the company targets better patient outcomes by harnessing analytics, machine learning, and other digital tools.

Patient outcomes are taking over from products and services as the focus of healthcare. But reorienting away from product development toward a holistic approach to patients demands the convergence of data from every part of the healthcare system. In this interview, part of our Biopharma Frontiers series on how the pharmaceutical industry is evolving, Jared Josleyn, global head of corporate development at Alphabet-owned Verily Life Sciences, talks with Erasis Healthcare about the need to integrate health data and apply it to patients’ lives in ways that achieve enduring impact.

Ecosystem focus area

Each project we take on is allocated a Erasis Project Manager (PM) who remains fully responsible to deliver your project as per the specifications required and within the timeframes agreed at the outset. Your PM oversees all aspects of the project utilising our customised Erasis Project Management System (PMS) an Internet-based system accessible by all our clients. Our PMS is a highly secure 128-bit encryption system where information can be uploaded and messages sent 24x7.

Our unique “Point-to-Point Methodology” means we move quickly and efficiently in grasping briefs, defining messages and delivering solutions. This is also reflected in our work and ability to deliver “bottom line” profits for our clients. This unique success formula means our clients keep coming back for more, asking us to do it again (and again).

Verily's mission

Verily is a data healthcare company that extracts high-fidelity data from the healthcare ecosystem and applies it to patients’ lives to improve human health. Everybody today talks about the need to focus on patient outcomes, but a lot of those conversations break down because of a lack of high-quality, longitudinal data—because we don’t know how well people manage their diseases on a daily basis, or we don’t understand comorbidities across different chronic diseases well enough, and so we can’t predict the effect a treatment will have on a patient population. Right now, data sets, whether from pharmaceutical companies, hardware companies, clinical workflows, or patients, sit separately within the ecosystem, which doesn’t effectively enable a true outcomes-based model that properly aligns incentives for all parties so that patients arrive at optimal outcomes. Verily’s purpose is to collect and integrate these massive and disparate data sets, observe new patterns, extract insights, and provide those insights to clinicians and patients to enable better management of health and disease.